Morgan Stanley analyst Sean Laaman upgrades ResMed (NYSE:RMD) from Equal-Weight to Overweight and announces $169price target.A great result - treated like ..Copyright © Benzinga. All rights reserved. Write to [email protected] with any questions about this content. Benzinga does not provide investment advice.
© 2023 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserve
5% layoff. Margins will see better days
lets have some RMD..
First Quarter (23/24) Results, page-31
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.15 |
Change
-0.250(0.80%) |
Mkt cap ! $19.86B | |||
| Open | High | Low | Value | Volume |
| $31.04 | $31.24 | $31.02 | $39.95M | 1.284M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 1939 | $31.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.15 | 395 | 9 |
View Market Depth
| Last trade - 15.00pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$31.11 |
Change
-0.250 ( 0.71 %) |
||||
| Open | High | Low | Volume | ||
| $31.03 | $31.23 | $31.02 | 87203 | ||
| Last updated 15.18pm 03/06/2024 ? | |||||
| RMD (ASX) Chart |